Novartis ownership secukinumab?

Who owns secukinumab, and what is Novartis’s role?

Secukinumab (brand name Cosentyx) is a biologic medicine developed and marketed by Novartis. Novartis holds the rights to the product and is the company associated with its commercialization and global supply. [1]

Is secukinumab licensed to other companies in different countries?

The information provided here only indicates Novartis’s association with the drug’s ownership/marketing. Details about sublicenses or local marketing partners by country are not included in the available sources. [1]

Does Novartis still control the drug’s patents and exclusivity?

No patent-by-patent status or exclusivity timeline is included in the provided information, so the current legal control beyond Novartis being the associated company for secukinumab cannot be confirmed here. [1]

Where to verify Novartis’s ownership for Cosentyx?

For ownership and commercial responsibility, the most direct checks are:
- the official product page for Cosentyx on Novartis’s website, and
- regulatory drug databases that list the marketing authorization holder (MAH). [1]

Sources:
[1] https://www.novartis.com/our-company/our-brands/cosentyx